PSMA

Cat. No.

A65449

CAS No.

3110124-60-9

PDI2

Synonyms: PSMA-DOTA-PEI2

PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that functions as a tumor retention agent and imaging agent while reducing renal uptake. It selectively binds to PSMA on prostate cancer cells, facilitating entry through clathrin-dependent endocytosis, which results in increased tumor retention and decreased renal accumulation. PDI2 is valuable for research in prostate cancer and castration-resistant metastatic prostate cancer, particularly in the context of SPECT diagnostic imaging and radiotheranostics.

Cat. No.

A65450

CAS No.

949575-22-8

MIP-1095

Synonyms: RPS-001

MIP-1095 is a potent inhibitor of prostate-specific membrane antigen (PSMA), specifically targeting its glutamate carboxypeptidase activity with a Ki of 0.24 nM. This compound is valuable in research applications focused on prostate cancer, facilitating studies on PSMA's role in tumor progression and its potential as a therapeutic target. MIP-1095 is essential for the development of PSMA-targeted diagnostics and therapeutics.

Cat. No.

A65451

CAS No.

1561171-59-2

PSMA-IN-4

PSMA-IN-4 is a potent inhibitor of prostate-specific membrane antigen (PSMA), exhibiting an IC50 value of 1.2 μM. This compound effectively interferes with PSMA activity, making it a valuable tool in research focused on prostate cancer diagnostics and therapeutics. Its specificity and potency support investigations into PSMA's role in tumor biology and its potential as a therapeutic target.

Cat. No.

A65452

CAS No.

151763-64-3

Capromab

Capromab is a monoclonal antibody targeting the intracellular domain of prostate-specific membrane antigen (PSMA). It exhibits specificity for necrotic cells with compromised membranes and does not undergo internalization upon binding. Capromab is utilized in research focused on prostate cancer, aiding in studies related to tumor progression and targeted therapies.

Cat. No.

A65453

CAS No.

2756661-48-8

PSMA ligand 3

PSMA Ligand 3 is a ligand specifically targeting Prostate-Specific Membrane Antigen (PSMA). Its primary function is to bind to PSMA, facilitating the detection and imaging of prostate cancer cells. This compound is valuable in cancer research, particularly in the study of prostate cancer diagnostics and therapy.

Cat. No.

A65454

CAS No.

3049900-51-5

PSMA binder-3

PSMA binder-3 is a selective binder for Prostate-Specific Membrane Antigen (PSMA), a key target in prostate cancer research. This high-affinity ligand exhibits strong binding capabilities that facilitate the study of PSMA's role in tumor biology and therapeutic targeting. It is an essential tool for applications in imaging and drug development related to prostate cancer.

Cat. No.

A65455

CAS No.

3036415-37-6

PSMA-trillium

Synonyms: Felivotide mopaxetan

PSMA-trillium is a PSMA-targeting compound that features a PSMA binder, a Macropa chelating molecule, and a pharmacokinetics modifier. This non-radioactive derivative of Actinium-225-PSMA-Trillium (BAY 3563254) offers enhanced PSMA targeting and optimized pharmacokinetic properties. PSMA-trillium effectively binds to Ac via the Macropa chelator and serves as a potent inhibitor of metastatic castration-resistant prostate cancer (mCRPC). It is a valuable tool for research into targeted therapies for prostate cancer.

Cat. No.

A65456

CAS No.

3055338-52-5

BQ0413

BQ0413 is a potent PSMA tracer with a dissociation constant (KD) of 89 pM, demonstrating strong affinity for the prostate-specific membrane antigen. This compound exhibits efficient cellular uptake and a notable internalization rate of 44% in PC3-pip cells, making it suitable for research applications in tumor imaging. When radiolabeled with 99mTc, BQ0413 serves as an effective imaging agent for prostate cancer in preclinical studies.

Cat. No.

A65457

CAS No.

3092260-02-8

PSMA-N5

PSMA-N5 is a potent PSMA ligand, exhibiting a Ki value of 0.71 nM. This compound serves as a PET radiotracer specifically for imaging prostate cancer, facilitating the visualization of tumors. PSMA-N5 is valuable for research applications in prostate cancer and other malignancies associated with prostate-specific membrane antigen.

Cat. No.

A65458

CAS No.

2946600-14-0

PSMA-IN-2

PSMA-IN-2 is a potent inhibitor of Prostate-Specific Membrane Antigen (PSMA) with a Ki value of 1.07 nM. This compound exhibits promising in vivo near-infrared (NIR) imaging properties at an emission wavelength of 1088 nm and an excitation wavelength of 808 nm. PSMA-IN-2 is particularly applicable in NIRII image-guided tumor resection surgeries in models of PSMA-positive tumors, making it a valuable tool for cancer research and therapeutic interventions.

Cat. No.

A65459

CAS No.

2941187-68-2

PSMA-IN-3

PSMA-IN-3 is a high-affinity inhibitor of Prostate-Specific Membrane Antigen (PSMA), demonstrating an IC50 value of 13 nM. This compound is particularly relevant for the development of 18F-labeled radioligands for positron emission tomography (PET) imaging to detect PSMA expression in prostate cancer. Researchers can utilize PSMA-IN-3 for studies aimed at advancing diagnostic imaging and therapeutic strategies in oncology.

Cat. No.

A65460

CAS No.

564482-79-7

DCFBC

DCFBC is a potent prostate-specific membrane antigen (PSMA) inhibitor, primarily utilized for small animal positron emission tomography (PET) imaging applications. Labeled with fluorine-18, [18F]DCFBC demonstrates preferential uptake in PSMA-expressing tumors, particularly in PIP tumors, while showing minimal uptake in FLU tumors. Additionally, while high accumulation in the kidneys and bladder is observed, the washout of radioactivity is faster compared to PIP tumors. This specificity positions [18F]DCFBC as a valuable tool for studying prostate cancer and assessing PSMA-targeted therapies.

Cat. No.

A65461

CAS No.

2647371-60-4

(R)-Zadavotide guraxetan

Synonyms: (R)-PSMA I&T; (R)-PNT-2002

(R)-Zadavotide guraxetan is a potent inhibitor of prostate-specific membrane antigen (PSMA), exhibiting significant antitumor activity. It is primarily utilized in research focused on prostate cancer, contributing to the understanding of targeted therapeutic approaches. This compound serves as a valuable tool for investigating the role of PSMA in cancer biology and evaluating efficacy in preclinical studies.

Cat. No.

A65462

CAS No.

3077205-52-5

PSMA-MAL-5

PSMA-MAL-5 is a prostate-specific membrane antigen (PSMA) ligand that covalently binds to Cys466 of the PSMA protein. This compound demonstrates significant biological activity, including high radiostability and tumor uptake when labeled with 177Lu and 225Ac. PSMA-MAL-5 is also effective in inhibiting tumor growth, making it suitable for applications in SPECT/CT imaging and radionuclide therapy for prostate cancer.

Cat. No.

A65463

CAS No.

1423622-48-3

PSMA precursor-1

PSMA precursor-1 is a key intermediate in the synthesis of prostate-specific membrane antigen (PSMA) ligands and fluorescent probes. It is utilized for the detection of PSMA in prostate cancer cell lines, specifically LNCaP and PC3. This compound plays a significant role in the development of targeted imaging agents and therapeutic strategies for prostate cancer research.

Cat. No.

A69590

CAS No.

5796-17-8

D-Dopa

Synonyms: 3-Hydroxy-D-tyrosine

D-Dopa (3-Hydroxy-D-tyrosine) is a potent, non-competitive allosteric inhibitor of glutamate carboxypeptidase II (GCPII), demonstrating an IC50 of 200 nM. This compound is known to elevate brain dopamine levels and induce turning behavior in rat models. Additionally, D-Dopa shows inhibitory effects against severe fever with thrombocytopenia syndrome (SFTS) virus infection. It serves as a valuable reagent for research applications in neurological diseases and viral infections.

Cat. No.

A69591

CAS No.

378242-00-3

E2072

E2072 is a selective, orally active competitive inhibitor of glutamate carboxypeptidase II (GCPII) with a Ki value of 10 nM. This compound has demonstrated efficacy in alleviating established thermal hyperalgesia in a rat model of chronic constriction injury. Additionally, E2072 has been shown to prevent oxaliplatin-induced reductions in nerve conduction velocity and amplitude in mice. It is suitable for research applications focused on neuropathic pain and neuropathy.

Cat. No.

A69596

CAS No.

373645-42-2

2-PMPA sodium

Synonyms: 2-(Phosphonomethyl)pentanedioic acid sodium

2-PMPA sodium is a potent inhibitor of glutamate carboxypeptidase II (GCPII) with an IC50 of 0.0003 μM. This compound effectively blocks the hydrolysis of N-acetylaspartylglutamate (NAAG), thereby modulating glutamate levels within the brain and influencing neurovascular coupling. Due to its specific action on GCPII, 2-PMPA sodium is valuable for investigating neurological diseases and understanding their underlying mechanisms. However, it is noted for its limited permeability across the blood-brain barrier, which may inform experimental design in related research.